WOCKPHARMA2023-07-012023-09-30 WOCKPHARMA2023-07-012023-09-30 WOCKPHARMA2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2023-09-30 WOCKPHARMA2023-07-012023-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2023-07-012023-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member WOCKPHARMA2023-07-012023-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss03Member WOCKPHARMA2023-07-012023-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2023-07-012023-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member WOCKPHARMA2023-07-012023-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss03Member WOCKPHARMA2023-07-012023-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2023-07-012023-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532300 WOCKPHARMA NA Wockhardt Limited Equity 2023-04-01 2024-03-31 2023-11-14 2023-11-06 INR Crores Half yearly 11:30:00 14:00:00 2023-11-14 2023-11-14 true Cash Flow Indirect Not applicable Single segment Pharmaceuticals 2023-07-01 2023-09-30 Unaudited Consolidated 7530000000.00 240000000.00 7770000000.00 1790000000.00 1050000000.00 30000000.00 1660000000.00 760000000.00 550000000.00 2280000000.00 8120000000.00 -350000000.00 0.00 -350000000.00 20000000.00 360000000.00 380000000.00 0.00 -730000000.00 0.00 0.00 0.00 0.00 -730000000.00 -200000000.00 -930000000.00 -770000000.00 40000000.00 -950000000.00 20000000.00 720000000.00 5 -5.37 -5.37 0.00 0.00 -5.37 -5.37 0.00 0.00 0.00 Notes To Consolidated Results:- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 14, 2023. The results have been subjected to limited review by the Statutory Auditors of the Company. 2) The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute ‘the Group’) and are prepared by applying Ind AS 110 - Consolidated Financial Statements . 3) During the previous year ended March 31, 2023, subsequent to the settlement agreement with the State of Texas on February 8, 2022, the Group had agreed for an early payment schedule for the settlement of the liability. Pursuant to this revision, Group had recorded an additional cost of Rs.11 crores due to unwinding of the discount (basis the original payment schedule) and has disclosed this as 'Exceptional items'. 4) During the previous year ended March 31, 2023, the Group has provided/ incurred loss of Rs. 123 crores w.r.t property , plant and equipment sold/ held for sale, Rs. 17 crores for inventory, Rs. 80 crores for claims incurred/ expected claims from customers and Rs. 13 crores for other costs pursuant to the restructuring of business in USA and has disclosed these as 'Exceptional items'. 5) The Company had accounted for a contract asset of Rs. 50 crores pursuant to a contract manufacturing agreement The Customer is yet to fulfill its contractual obligations and commitments. Though, the Company is pursuing various options and taking necessary actions related to this matter, given the uncertainty, Company had provided for this contract asset in the previous year and this was disclosed as 'Exceptional items'. Company had also purchased certain specific inventory for this contract which has not been used. Company is continuing to evaluate alternate options to liquidate/ utilize such inventory, pending which, during the previous quarter, the Company has made a provision of Rs. 14 crores for such inventory basis the current assessment and information available as on date. This expenditure is also reported as ‘Exceptional items’. 6) During the quarter ended September 30, 2023 , the Company has allotted Nil ( Year to date: 6,250) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options. 7)Key Financials on Standalone basis: (Rs. in crores) Particulars 3 months 3months 3 months 6 months 6 months year ended ended 30.09.23 ended 30.06.23 ended 30.09.22 ended 30.09.23 ended 30.09.22 31.03.23 Unaudited unadited unaudited unaudited unadited audited Total Income 266 257 287 523 577 1,139 Loss before (107) (115) (115) (222) (169) (513) tax Loss after (107) (115) (75) (222) (112) (466) tax Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com ) and also on the Company's website www.wockhardt.com. 8) The Group is exclusively into Pharmaceutical business Segment. 9) For List of Subsidiaries as on September 30, 2023 please refer Annexure. Single segment 2023-04-01 2023-09-30 Unaudited Consolidated 13970000000.00 360000000.00 14330000000.00 3160000000.00 2550000000.00 -20000000.00 3200000000.00 1550000000.00 1100000000.00 4180000000.00 15720000000.00 -1390000000.00 -140000000.00 -1530000000.00 110000000.00 450000000.00 560000000.00 0.00 -2090000000.00 0.00 0.00 0.00 0.00 -2090000000.00 -210000000.00 -2300000000.00 -2110000000.00 20000000.00 -2290000000.00 -10000000.00 720000000.00 5 -14.65 -14.65 0.00 0.00 -14.65 -14.65 0.00 0.00 0.00 Other Expenses 2280000000.00 Other Expenses 4180000000.00 3070000000.00 19290000000.00 4190000000.00 0.00 9330000000.00 580000000.00 11970000000.00 0.00 0.00 0.00 0.00 0.00 620000000.00 620000000.00 5640000000.00 2210000000.00 53830000000.00 6350000000.00 0.00 7140000000.00 540000000.00 300000000.00 0.00 310000000.00 8290000000.00 0.00 2750000000.00 17390000000.00 2980000000.00 0.00 74200000000.00 720000000.00 30530000000.00 31250000000.00 34320000000.00 9680000000.00 0.00 1990000000.00 11670000000.00 280000000.00 330000000.00 0.00 750000000.00 13030000000.00 10350000000.00 8000000000.00 6570000000.00 24920000000.00 1330000000.00 460000000.00 140000000.00 0.00 26850000000.00 0.00 0.00 39880000000.00 74200000000.00 Notes to Assets Liabilities: 1. Property, Plant and Equipment of Rs.1929 crore includes Right of use assets amounting to Rs. 432 crore. 2. Other non-current assets of Rs. 221 crore includes Non-current tax assets (net) amounting to Rs. 114 crore. 3. Other non-current financial liabilities consists of Lease liabilities amounting to Rs.199 crore. 4. Other current financial liabilities of Rs. 657 crore include Lease liabilities amounting to Rs.72 crore. 5. Non-current assets classified as held for sale represents Assets classified as held for sale. Please also, additionally refer to the Statement of Consolidated Unaudited Results for the quarter and half year ended September 30, 2023 as attached to the Outcome of Board Meeting. Notes to Cash Flow Statements 1.Adjustments for unrealised foreign exchange losses and gain consists of Net foreign exchange fluctuation loss / (gain), net Rs. 13 crore. 2. Proceeds from issuance of shares includes transaction cost relating to Right Issue of Rs. 1 Crore. 3. Proceeds from borrowing of Rs. 257 crore includes proceeds from short term borrowings Rs.35 crore and loan from Related Parties long term of Rs. 222 crore. 4.Repayment of borrowing Rs.179 crore includes repayment of long term borrowings Rs.121 crore, repayment of loan taken from Related Parties-long term Rs. 11 crore and short term Rs.47 crore. 5.Other inflows (outflows) of cash consists of Finance cost paid Rs. 89 crore. 6.Aggregated/segregated in accordance with the prescribed format and to the extent is the requirement of the accounting standard. Please also, additionally refer to the Statement of Consolidated Unaudited Results for the quarter and half year ended September 30, 2023 as attached to the Outcome of Board Meeting 1550000000.00 120000000.00 670000000.00 0.00 0.00 350000000.00 0.00 0.00 0.00 0.00 0.00 -1210000000.00 0.00 1100000000.00 0.00 0.00 0.00 0.00 0.00 -130000000.00 0.00 20000000.00 10000000.00 0.00 0.00 0.00 0.00 310000000.00 0.00 2750000000.00 1220000000.00 0.00 0.00 0.00 180000000.00 0.00 1040000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 120000000.00 0.00 0.00 0.00 820000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10000000.00 0.00 50000000.00 0.00 -880000000.00 0.00 0.00 -10000000.00 0.00 0.00 0.00 0.00 0.00 2570000000.00 1790000000.00 0.00 380000000.00 0.00 890000000.00 0.00 0.00 -500000000.00 -340000000.00 -20000000.00 -360000000.00 900000000.00 540000000.00 Items that will not be reclassified to Profit or Loss -(charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset) 4400000.00 Income tax relating to items that will not be reclassified to Profit or Loss -credit/(charge) 0.00 Rounding Off -4400000.00 Items that will not be reclassified to Profit or Loss -(charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset) 10000000.00 Income tax relating to items that will not be reclassified to Profit or Loss -credit/(charge) 0.00 Rounding Off 0.00 0.00 10000000.00 0.00 0.00 Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations) (Continued operations) -200000000.00 Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations) (Continued operations) -220000000.00 -200000000.00 -220000000.00 0.00 0.00